SAN JOSE, Calif., Feb. 18, 2020 /PRNewswire/ -- Aridis
Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company
focused on the discovery and development of novel anti-infective
therapies to treat life-threatening bacterial infections, announced
today that it will host an Investor Day on Thursday, March 12th, 2020 in
New York City from 12:00PM-2:00PM EST.
The event will provide development updates on the Company's key
clinical programs and feature key opinion leader (KOL) panels
moderated by leading healthcare analysts, Louise Chen of Cantor Fitzgerald and
Jason McCarthy from Maxim Group.
Participating experts include Dr. Steven
Opal of Brown University and Dr.
Lisa Saiman of Columbia University who will provide insights on
the acute pneumonia and cystic fibrosis indications and the current
therapeutic landscape. Medical reimbursement will also be
discussed.
In addition to the KOL panel discussion, the forum is intended
to provide investors and analysts with a comprehensive profile of
APEX™, the Company's cutting-edge antibody discovery
and production platform along with an update on lead programs
AR-301 for the treatment of ventilator associated pneumonia (VAP)
and AR-501, an inhalable therapy for chronic lung infections in
cystic fibrosis patients. Aridis is advancing AR-301 in a global
clinical trial which remains on track to report top line data in 1H
2021, and enrolling AR-501's Phase 1/2a clinical trial with
top-line data expected in 1H 2020 (healthy subjects), and in 2H
2021 (cystic fibrosis subjects).
To learn more about the event or to register for attendance,
please email RSVP@aridispharma.com.
About Aridis Pharmaceuticals, Inc.
Aridis
Pharmaceuticals, Inc. discovers and develops anti-infectives to be
used as add-on treatments to standard-of-care antibiotics. The
Company is utilizing its proprietary APEX™ and MabIgX®
technology platforms to rapidly identify rare, potent
antibody-producing B-cells from patients who have successfully
overcome an infection, and to manufacture mAbs for therapeutic
treatment of critical infections. These mAbs are already of human
origin and functionally optimized for high potency by the donor's
immune system; hence, they do not require genetic engineering or
further optimization to achieve full functionality.
The Company has generated multiple clinical stage mAbs targeting
bacteria that cause life-threatening infections such as
VAP and HAP. The use of mAbs as anti-infective treatments
represents an innovative therapeutic approach that harnesses the
human immune system to fight infections and is designed to overcome
the deficiencies associated with the current standard of care which
is broad spectrum antibiotics. Such deficiencies include, but are
not limited to, increasing drug resistance, short duration of
efficacy, disruption of the normal flora of the human microbiome
and lack of differentiation among current treatments. The mAb
portfolio is complemented by a non-antibiotic novel mechanism small
molecule anti-infective candidate being developed to treat lung
infections in cystic fibrosis patients. The company's pipeline is
highlighted below:
Aridis' Pipeline
AR-301 (VAP). AR-301 is a fully human
immunoglobulin 1, or IgG1, mAb currently in Phase 3 clinical
development targeting gram-positive S.
aureus alpha-toxin in VAP patients.
AR-101 (HAP). AR-101 is a fully human
immunoglobulin M, or IgM, mAb targeting P.
aeruginosa liposaccharides serotype O11, which accounts
for approximately 22% of all P.
aeruginosa hospital acquired pneumonia cases
worldwide.
AR-501 (cystic fibrosis). AR-501 is an inhaled
formulation of gallium citrate with broad-spectrum anti-infective
activity being developed to treat chronic lung infections in cystic
fibrosis patients. This program is currently in a Phase 1/2a
clinical study in healthy volunteers and CF patients.
AR-401 (blood stream infections). AR-401 is a
fully human mAb preclinical program aimed at treating infections
caused by gram-negative Acinetobacter baumannii.
AR-201 (RSV infection). AR-201 is a fully human IgG1
mAb preclinical program aimed at neutralizing diverse clinical
isolates of respiratory syncytial virus (RSV).
For additional information on Aridis Pharmaceuticals, please
visit https://aridispharma.com/.
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. These statements may be
identified by the use of words such as "anticipate," "believe,"
"forecast," "estimated" and "intend" or other similar terms or
expressions that concern Aridis' expectations, strategy, plans or
intentions. These forward-looking statements are based on Aridis'
current expectations and actual results could differ materially.
There are a number of factors that could cause actual events
to differ materially from those indicated by such forward-looking
statements. These factors include, but are not limited to,
the timing of regulatory submissions, Aridis' ability to obtain and
maintain regulatory approval of its existing product candidates and
any other product candidates it may develop, approvals for clinical
trials may be delayed or withheld by regulatory agencies, risks
relating to the timing and costs of clinical trials, risks
associated with obtaining funding from third parties, management
and employee operations and execution risks, loss of key personnel,
competition, risks related to market acceptance of products,
intellectual property risks, risks associated with the uncertainty
of future financial results, Aridis' ability to attract
collaborators and partners and risks associated with Aridis'
reliance on third party organizations. While the list of
factors presented here is considered representative, no such list
should be considered to be a complete statement of all potential
risks and uncertainties. Unlisted factors may present significant
additional obstacles to the realization of forward-looking
statements. Actual results could differ materially from those
described or implied by such forward-looking statements as a result
of various important factors, including, without limitation, market
conditions and the factors described under the caption "Risk
Factors" in Aridis' 10-K for the year ended December 31, 2018 and Aridis' other filings
made with the Securities and Exchange
Commission. Forward-looking statements included herein are
made as of the date hereof, and Aridis does not undertake any
obligation to update publicly such statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations
Jason Wong
Blueprint Life Science Group
jwong@bplifescience.com
(415) 375-3340 Ext. 4
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aridis-pharmaceuticals-to-host-investor-day-showcasing-apex-technology-platform-and-key-opinion-leader-panels-on-cystic-fibrosis-and-pneumonia-301005793.html
SOURCE Aridis Pharmaceuticals, Inc.